Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Gilead Sciences (NQ: GILD )

72.50 -0.06 (-0.08%)
Streaming Delayed Price Updated: 12:55 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,305,624
Open 72.89
Bid (Size) 72.49 (2)
Ask (Size) 72.51 (1)
Prev. Close 72.56
Today's Range 72.02 - 73.32
52wk Range 62.07 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 4.14%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
Via Benzinga
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
From Gilead Sciences, Inc.
Via Business Wire

Performance

YTD
-12.90%
-12.90%
1 Month
+2.59%
+2.59%
3 Month
+8.29%
+8.29%
6 Month
-7.56%
-7.56%
1 Year
-6.64%
-6.64%

More News

Read More
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
Via The Motley Fool
Topics ETFs
Check Out What Whales Are Doing With GILD
Via Benzinga
Gilead Sciences's Options Frenzy: What You Need to Know
Via Benzinga
Looking Into Gilead Sciences's Recent Short Interest
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $8,400 Today
Via Benzinga
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
Via InvestorPlace
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
From Gilead Sciences, Inc.
Via Business Wire
Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays
Via The Motley Fool
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
Key Takeaways From Gilead Sciences Analyst Ratings
Via Benzinga
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
Via InvestorPlace
Positive News is Driving This Cancer Drug Maker’s Stock Higher
Via MarketBeat
3 Dividend Growth Stocks to Buy and Hold
Via The Motley Fool
Is Iovance Biotherapeutics a Millionaire Maker?
Via The Motley Fool
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
Via InvestorPlace
3 Underappreciated Stocks About to Break Their Chains
Via InvestorPlace
Oil Declines Amid Prospects Of An Agreement Between Israel And Hamas. Powell Will Address The Us Congress Today
Via Talk Markets
Topics Stocks
Exposures US Equities
7 Cheap Biotech Stocks With Major Upside Potential
Via InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Via Talk Markets
This Domino's Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Amgen, Inc. Dividend Stock Analysis
Via Talk Markets
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Via InvestorPlace
Exposures Product Safety
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.